Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biofrontera Inc.'s SEC filings provide detailed disclosure of its photodynamic therapy commercialization progress, clinical development expenditures, and the specialized regulatory environment governing dermatological pharmaceutical products. For a specialty pharmaceutical company with a focused product portfolio, these filings reveal revenue trends from Ameluz and Xepi sales, research and development investments in clinical trials, and the company's strategy for expanding approved treatment indications.
The company's 10-K annual reports detail its drug development pipeline status, patent protection timelines, manufacturing dependencies, and the competitive landscape for actinic keratosis treatments. Investors examining these filings can assess how effectively the company converts clinical trial results into FDA approvals and subsequently drives physician adoption within dermatology practices. The Management's Discussion and Analysis sections explain factors affecting prescription volume trends, reimbursement dynamics with insurers and pharmacy benefit managers, and the company's commercial strategy for expanding market penetration.
Form 10-Q quarterly reports track Ameluz sales performance, operating expense patterns, and progress milestones in ongoing Phase 3 clinical trials. Given the binary nature of pharmaceutical development, where FDA approval decisions can dramatically affect company valuation, these quarterly disclosures provide critical updates on clinical trial enrollment rates, data readout timing, and regulatory submission plans.
8-K current reports announce material events including clinical trial results, FDA communications, financing transactions, and NASDAQ listing compliance matters. For a development-stage biopharmaceutical company, Form 8-K filings often contain the most time-sensitive information affecting investment decisions. Form 4 insider transaction reports reveal whether executives and directors are accumulating or reducing their equity positions, particularly around significant clinical or regulatory milestones.
Our AI summarizes complex pharmaceutical development disclosures, highlights revenue segment performance, and explains the implications of FDA correspondence and clinical trial outcomes found across these regulatory filings.
Wilhelm Konrad Thomas Zours filed an initial Section 16 Form 3 reporting indirect beneficial ownership in Biofrontera Inc. (BFRI). He reports 400,000 common shares held by Biofrontera AG and 58,884 common shares held by Deutsche Balaton Aktiengesellschaft, both held indirectly. He also reports convertible preferred stock exercisable into 4,831,172 common shares at $0.6249 per share; the preferred has no expiration but conversion is capped to avoid >19.99% ownership on conversion. The filing includes managerial roles and ownership chains explaining indirect holdings.
Deutsche Balaton Aktiengesellschaft filed an Initial Statement of Beneficial Ownership reporting direct ownership of 58,884 shares of Biofrontera Inc. (BFRI) and indirect ownership of 400,000 common shares
The filer also reports indirect beneficial ownership of 4,831,172 common shares underlying Series D Convertible Preferred Stock convertible at $0.6249 per share, held by Biofrontera AG. The filer states it and affiliates control ~62.2% of Biofrontera AG voting stock and disclaims direct beneficial ownership except for indirect pecuniary interest. The preferred has no expiration and conversion is limited to prevent over 19.99% ownership on conversion.
Maria del Pilar de la Huerta Martinez filed an Initial Statement of Beneficial Ownership on Form 3 reporting indirect holdings in Biofrontera Inc. (BFRI). The filing states 400,000 shares of common stock are held indirectly by Biofrontera AG and the reporting person may be deemed to beneficially own those shares because she is the sole member of the management board of Biofrontera AG. The filing also reports ownership of Series D convertible preferred stock convertible into 4,831,172 shares of common stock at a conversion price of $0.0006 per share; the preferred is convertible at any time and has no expiration date. The reporting person is identified as a director and a 10% owner for the issuer, and disclaims direct beneficial ownership except for any indirect pecuniary interest. The filing notes that Biofrontera AG has the right to appoint a board representative and that Dr. Heikki Lanckriet has been deputized and filed a separate Section 16 report.
Biofrontera, Inc. reported results from a special shareholder meeting where shareholders holding 8,403,861 votes were present for proposals one, three, and four, and shareholders holding 6,820,211 votes were present for proposal two, constituting a quorum for all proposals. The filing states that the meeting was solicited under Regulation 14A and that there was no solicitation in opposition. The proxy statement filed on August 5, 2025 is cited as the source for the detailed descriptions of the proposals. The document indicates that the meeting "summarizes all matters voted on," but it does not include the vote tallies or explicit outcomes for each proposal within the provided text.
Biofrontera AG and related Reporting Persons disclosed substantial potential ownership of Biofrontera Inc. common stock through conversion rights in Series D Convertible Preferred Stock. BFAG holds 3,019 shares of Series D Preferred Stock convertible, subject to a conversion cap, into up to 4,831,172 common shares but limited by a Maximum Percentage of 19.99%, which currently yields beneficial ownership of 2,493,346 shares (19.54%). Collectively certain Reporting Persons report beneficial ownership of 2,552,230 shares (19.99%). The Series D conversion follows a September 16, 2025 stockholder approval; conversion economics equal $1,000 divided by $0.6249 per share prior to rounding. The Agreement transferring U.S. rights to Ameluz and RhodoLED includes a royalty structure of 12% if U.S. Ameluz revenue is under $65.0 million and 15% if above that threshold. Reporting Persons disclaim formation of a group while acknowledging interlocking ownership and governance relationships.
Biofrontera AG reported acquiring 3,019 shares of Series D convertible preferred stock on 09/16/2025 in a privately negotiated transaction in exchange for assets related to U.S. production and sale of certain products with an estimated market value of $3,019,000. The Series D preferred is convertible at any time at the holder's election and has no expiration date. After the transaction the reporting person beneficially owned 4,831,172 shares of common stock and 3,019 derivative securities. The reporting entity is a director and >10% owner and has an agreement allowing it to appoint one director; Dr. Heikki Lanckriet has been deputized to serve on the issuer's board.
George Patrick Jones, identified as Chief Commercial Officer and Director of Biofrontera Inc. (BFRI), was granted an employee stock option on 09/15/2025 to purchase 100,000 shares of common stock at a $1 exercise price. The option has an expiration date of 08/25/2035 and becomes exercisable in two equal vesting installments: February 25, 2026 and August 25, 2026. Following the reported transaction, Mr. Jones beneficially owns 100,000 option shares on a direct basis. The Form 4 was signed by an attorney-in-fact, Daniel Hakansson, on 09/16/2025.
George Patrick Jones, listed at 120 Presidential Way, Suite 330, Woburn MA 01801, filed an initial Form 3 for Biofrontera Inc. (BFRI) reporting an event date of 08/25/2025. He is identified as a Director and Chief Commercial Officer. The filing states no securities are beneficially owned. The form was executed by an attorney-in-fact, Daniel Hakansson, on 09/16/2025.
Kevin D. Weber, a director of Biofrontera Inc. (BFRI), received a grant of employee stock options on 07/22/2025. The grant comprises 20,000 options with an exercise price of $1.00 per share and an expiration date listed as 07/22/2035. The form shows 20,000 common shares beneficially owned following the reported transaction and indicates ownership is held directly. The filer states the option "vests in twelve equal monthly installments beginning on August 22, 2025." The filing was signed on behalf of Mr. Weber by an attorney-in-fact on 09/16/2025. Other options with different terms are not included.
Hermann Luebbert, CEO & Chairman and director of Biofrontera Inc. (BFRI), reported equity awards and option grants during 2024–2025. The Form 4 shows a 07/22/2025 grant of 125,000 restricted stock units (RSUs) and a contemporaneous employee stock option to buy 125,000 shares at $1.00 (exercise through 07/22/2035). On 09/10/2025 a transaction coded "M" reports acquisition of 137,500 shares (via conversion or settlement of RSUs). The RSUs convert one-for-one into common stock and were received for no consideration; some RSUs vest in two equal yearly installments beginning July 22, 2026, and other RSUs granted July 12, 2024 vest beginning July 12, 2025. Vested RSUs may be settled in shares, cash, or a combination within 60 days of vesting. The reporting was signed by an attorney-in-fact on 09/16/2025.
FAQ
What is the current stock price of Biofrontera (BFRI)?
What is the market cap of Biofrontera (BFRI)?
